Postnatal corticosteroid response in neonates < 32 weeks and relation with placental pathology.

Autor: Koenders VM; Isala Hospital (Neonatal Intensive Care Unit), Zwolle, The Netherlands. viviennekoenders@gmail.com., Appels A; Isala Hospital (Neonatal Intensive Care Unit), Zwolle, The Netherlands., van Straaten HLM; Isala Hospital (Neonatal Intensive Care Unit), Zwolle, The Netherlands., Dutman AC; Isala Hospital (Department of Pathology), Zwolle, The Netherlands., Hemels MAC; Isala Hospital (Neonatal Intensive Care Unit), Zwolle, The Netherlands.
Jazyk: angličtina
Zdroj: European journal of pediatrics [Eur J Pediatr] 2023 Jan; Vol. 182 (1), pp. 265-274. Date of Electronic Publication: 2022 Nov 01.
DOI: 10.1007/s00431-022-04672-9
Abstrakt: Acute chorioamnionitis and maternal vascular malperfusion are associated with an increased risk of bronchopulmonary dysplasia. To prevent bronchopulmonary dysplasia, postnatal corticosteroids are given to preterm neonates. Clinical observations indicate not all neonates respond to corticosteroids, the so-called non-responders. This study aimed to investigate the association between placental pathology and short-term response to postnatal corticosteroids in neonates < 32 weeks postconceptional age at risk for bronchopulmonary dysplasia. All neonates < 32 weeks born between 2009 and 2016, receiving corticosteroids in the course of BPD, were included. The preterm neonates were divided into three groups depending on placental histology: acute chorioamnionitis, maternal vascular malperfusion, or no placental pathology. Respiratory support was assessed prior to treatment and at days 4 and 7. A responder was defined as extubation within 7 days after starting corticosteroid treatment. In total, 52% of the chorioamnionitis neonates, 67% of the maternal vascular malperfusion neonates, and 58% of neonates in the no pathology group were responders. The odds ratio for extubation was 0.53 (0.18-1.55) at day 4 and 0.66 (0.23-1.97) at day 7, in the chorioamnionitis group compared to the maternal vascular malperfusion.
Conclusion: Short-term response to postnatal corticosteroids did not significantly differ between premature neonates born after acute chorioamnionitis, maternal vascular malperfusion, or no placenta pathology. However, a trend of better corticosteroid response in maternal vascular malperfusion neonates was found, potentially due to differences in prenatal pulmonary development and postnatal cortisol.
What Is Known: • Bronchopulmonary dysplasia is related to chorioamnionitis and maternal vascular malperfusion. • Corticosteroids remain an important treatment in the course of bronchopulmonary dysplasia despite conflicting results and non-responsiveness in some preterm neonates.
What Is New: • Non-responsiveness might be related to differences in pulmonary inflammation and systemic cortisol due to predispositions triggered by chorioamnionitis or maternal vascular malperfusion. • Neonates born after maternal vascular malperfusion seem to respond better to postnatal corticosteroid treatment.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje